{
    "clinical_study": {
        "@rank": "163004", 
        "arm_group": [
            {
                "arm_group_label": "Calcitriol + CaCO3", 
                "arm_group_type": "Experimental", 
                "description": "Calcitriol 0.25mcg 1cap daily for 8 weeks, and Calcium Carbonate 500mg 1tab 3 times daily for 8 weeks"
            }, 
            {
                "arm_group_label": "Calcitriol", 
                "arm_group_type": "Active Comparator", 
                "description": "Calcitriol 0.25mcg 1cap daily for 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Chronic kidney disease (CKD) is an established risk factor for cardiovascular morbidity and\n      mortality, as shown by common manifestations of left ventricular hypertrophy (LVH) and\n      arterial calcifications in CKD patients. Fibroblast growth factor-23(FGF-23) is a recently\n      identified phosphaturic hormone that has been reported to be associated with the development\n      of secondary hyperparathyroidism, cardiovascular morbidity, mortality, CKD progression.\n\n      While vitamin D is the mainstay therapy in CKD mineral bone disease (CKD-MBD), increased\n      FGF-23 levels have been reported with vitamin D administration. The purpose of this study\n      was to investigate the effect of calcium carbonate when used in conjunction with calcitriol\n      on FGF-23."
        }, 
        "brief_title": "Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Kidney Disease Stage 3", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults of 18~70 years of age\n\n          -  CKD stage 3 patients (GFR: 30-60ml/min/1.73m2)\n\n          -  Patients who've  given consent to the trial\n\n        Exclusion Criteria:\n\n          -  Known allergy to Vitamin D or calcium carbonate\n\n          -  Administration of vitamin D analogue or phosphate binders 3 months prior to study\n             entry\n\n          -  History of  hypercalcemia (corrected serum calcium > 10.5 mg/dL) or hypophosphatemia\n             (serum phosphate < 2.5 mg/dL) 3 months prior to study entry\n\n          -  Patients with bone pathologies or diseases requiring vitamin D therapy that is\n             unrelated to CKD-MBD\n\n          -  Administration of concurrent medication , diseases, or history of surgeries that may\n             affect bone-mineral metabolism or alter bone status\n\n          -  Patients diagnosed with rapidly progressive glomerulonephritis(RPGN) or those  in\n             need of renal replacement therapy\n\n          -  Patients with obstructive bowel diseases, or severe gastrointestinal diseases\n\n          -  Patients with less than 2 years of life expectancy(ex. Malignancy diseases)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01748396", 
            "org_study_id": "SNUH-FGF23"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Calcitriol + CaCO3", 
                    "Calcitriol"
                ], 
                "intervention_name": "Calcitriol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Calcitriol + CaCO3", 
                "intervention_name": "Calcium Carbonate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcitriol", 
                "Calcium, Dietary", 
                "Calcium Carbonate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "FGF-23", 
            "Calcitriol", 
            "Calcium carbonate", 
            "CKD Stage 3"
        ], 
        "lastchanged_date": "February 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Phosphate Binders on FGF-23 During Calcitriol Administration in CKD Stage 3 Patients", 
        "overall_official": [
            {
                "affiliation": "Seoul National University Hospital", 
                "last_name": "Yon Su Kim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "College of Pharmacy, Seoul National University", 
                "last_name": "Jung Mi Oh, Pharm.D.", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Comparison of percent changes in FGF-23 from baseline", 
            "measure": "Percent changes in FGF-23", 
            "safety_issue": "No", 
            "time_frame": "8 weeks after administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01748396"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Yon Su Kim", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Comparison of percent change in Ca from baseline", 
                "measure": "Percent changes in Ca", 
                "safety_issue": "No", 
                "time_frame": "8 weeks after administration"
            }, 
            {
                "description": "Comparison of percent change in P from baseline", 
                "measure": "Percent changes in P", 
                "safety_issue": "No", 
                "time_frame": "8 weeks after administration"
            }, 
            {
                "description": "Comparison of percent change in intact parathyroid hormone from baseline", 
                "measure": "Percent changes in iPTH", 
                "safety_issue": "No", 
                "time_frame": "8 weeks after administration"
            }, 
            {
                "description": "Comparison of percent change in 25(OH)D from baseline", 
                "measure": "Percent changes in 25(OH)D", 
                "safety_issue": "No", 
                "time_frame": "8 weeks after administration"
            }, 
            {
                "description": "Comparison of percent change in 1,25(OH)2D from baseline", 
                "measure": "Percent changes in 1,25(OH)2D", 
                "safety_issue": "No", 
                "time_frame": "8 weeks after administration"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}